Valuation: Emcure Pharmaceuticals Limited

Market Cap 356B 3.73B 3.35B 3.1B 2.81B 5.24B 5.3B 37.04B 14.75B 186B 14.01B 13.72B 591B P/E 2027 *
29.9x
P/E 2028 * 24.1x
Enterprise Value 362B 3.8B 3.41B 3.15B 2.86B 5.34B 5.4B 37.7B 15.02B 189B 14.26B 13.96B 601B EV / Sales 2027 *
3.41x
EV / Sales 2028 * 2.94x
Free-Float
22.18%
Yield 2027 *
0.21%
Yield 2028 * 0.25%
03/10 Emcure Pharmaceuticals Limited Receives Income-Tax Department Orders Imposing Aggregate Penalty of INR 577.396732 Million CI
23/09 Emcure Pharmaceuticals Limited Approves Final Dividend for the Financial Year Ended March 31, 2026 CI
16/09 Gilead Sciences Expands Licensing Agreements for HIV Treatment MT
07/08 Emcure Pharmaceuticals Limited, Q1 2027 Earnings Call, Aug 06, 2026
06/08 Emcure Pharmaceuticals Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026 CI
06/08 Emcure Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
06/08 Emcure Pharmaceuticals Limited Announces Board and Management Changes CI
21/07 Emcure Pharmaceuticals Limited Announces Cessation of P.S. Jayakumar as Independent Director and from Board Committees, Effective July 21, 2026 CI
21/07 Emcure Pharmaceuticals Limited completed the acquisition of an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh. CI
20/07 Emcure Pharmaceuticals Limited Expands Use Of Poviztra For MASH Indication Following CDSCO Approval CI
13/07 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from its shareholders. CI
13/07 Emcure Pharmaceuticals Limited executed a share transfer agreement to acquire an additional unknown minority stake in Gennova Biopharmaceuticals Ltd. from Sanjay Singh. CI
03/07 Emcure Pharmaceuticals Unit to Acquire Remaining Shares in Canada's Mantra Pharma for C$50 Million MT
1 day-0.01%
1 week+6.83%
Current month-3.50%
1 month-2.74%
3 months-0.91%
6 months+16.59%
Current year+37.41%
1 week 1,724.8
Extreme 1724.8
1,889.2
1 month 1,716
Extreme 1716
1,974
Current year 1,381
Extreme 1381
2,100.7
1 year 1,306.5
Extreme 1306.5
2,100.7
3 years 889
Extreme 889
2,100.7
5 years 889
Extreme 889
2,100.7
10 years 889
Extreme 889
2,100.7
Manager TitleAgeSince
Chief Executive Officer 75 16/04/1981
Director of Finance/CFO - 01/10/2003
Compliance Officer - 04/02/2026
Director TitleAgeSince
Director/Board Member 73 23/07/2001
Chairman 75 21/09/2026
Director/Board Member 72 16/04/2021
Change 5-day change 1-year change 3-year change Capi.($)
-0.01%+6.83%+41.40% - 3.73B
+0.50%+1.38%+57.09%+129.96% 1,148B
+0.86%+5.14%+45.00%+86.15% 652B
-0.14%+0.42%+25.69%+105.85% 505B
+0.70%+2.30%+54.03%+66.22% 384B
-0.63%-5.97%+61.93%+37.06% 348B
+3.26%+3.17%+34.98%+57.11% 294B
+1.43%-0.52%+2.80%+26.37% 264B
+0.87%+3.08%+54.69%+72.74% 244B
+0.08%+3.67%+35.05%+107.78% 197B
Average +1.06%+1.77%+41.27%+76.58% 404.09B
Weighted average by Cap. +1.00%+1.51%+44.95%+89.18%

Financials

2027 *2028 *
Net sales 106B 1.11B 999M 924M 837M 1.56B 1.58B 11.04B 4.4B 55.49B 4.18B 4.09B 176B 120B 1.26B 1.13B 1.04B 945M 1.77B 1.79B 12.48B 4.97B 62.7B 4.72B 4.62B 199B
Net income 11.89B 125M 112M 104M 93.82M 175M 177M 1.24B 493M 6.22B 469M 459M 19.76B 14.61B 153M 138M 127M 115M 215M 218M 1.52B 606M 7.64B 576M 563M 24.27B
Net Debt 6.38B 67.03M 60.14M 55.6M 50.36M 94.08M 95.22M 665M 265M 3.34B 252M 246M 10.61B -3.28B -34.42M -30.88M -28.55M -25.86M -48.31M -48.89M -341M -136M -1.72B -129M -126M -5.45B
Projected Income Statement - Annual - Emcure Pharmaceuticals Limited
Logo Emcure Pharmaceuticals Limited
Emcure Pharmaceuticals Limited is an India-based pharmaceutical company, which is engaged in developing, manufacturing and globally marketing a range of pharmaceutical products across several major therapeutic areas. It offers a range of products and services under formulations, biologics and Active Pharmaceutical Ingredient (APIs). It operates across a wide scope of areas, including Gynecology, Cardiovascular, HIV Antivirals, VMN (Vitamins, Minerals & Nutrients), Pain/Analgesics, Nephrology, Oncology, Anti-Infective, Respiratory, CNS. Its brands include Orofer XT and Pause (Gynecological), Proxym (pain), Tenectase (CNS), Vylda (diabetology), Vitanova (VMN). Its API products include S-Amlodipine, Ferric Carboxymaltose, Ferrous Ascorbate and Eribulin. Its biologics business offers various products, including Elaxim (Tenecteplase), Vintor (Erythropoietin), TENECTASE (Tenecteplase). It has developed two platforms: Mammalian and Microbial.
Employees
6,914
Date Price Change Volume
28/10/26 INR 1,875.00 -0.01% 62,133
27/10/26 INR 1,875.20 +5.34% 113,835
26/10/26 INR 1,780.20 +0.55% 138,616
23/10/26 INR 1,770.40 -0.68% 141,412
22/10/26 INR 1,782.60 +1.57% 113,203
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - Emcure Pharmaceuticals Limited
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
1,875.00INR
Average target price
2,229.38INR
Spread / Average Target
+18.90%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Emcure Pharmaceuticals Limited
  1. Stock Market
  2. Stocks
  3. EMCURE Stock